What is the half-life of retatrutide?
Approximately 6 days in human plasma. The Phase 1b first-in-human pharmacokinetics study (Urva et al., Lancet, 2022) established this half-life from multiple-ascending-dose PK data in adults with type 2 diabetes [4]. The ~6-day half-life is what supports once-weekly subcutaneous dosing in all Phase 2 and Phase 3 trials — a dose every 7 days maintains plasma concentrations within the therapeutic range studied.
What is retatrutide's half-life and how long does it stay in the body?
Half-life is approximately 6 days [4]. Half-life is the time it takes for the concentration of a drug in the blood to fall by 50%. At a 6-day half-life, it takes roughly 5–6 half-lives (approximately 30–36 days) for the compound to clear to near-undetectable levels after the last dose. This extended plasma residence is engineered by a C20 fatty-diacid chain on the peptide that binds retatrutide to albumin (the main carrier protein in blood), slowing its elimination.
What does retatrutide do?
Retatrutide activates three hormone receptors simultaneously: GIP (appetite and fat metabolism), GLP-1 (appetite suppression, insulin secretion, gastric slowing), and glucagon (energy expenditure, liver fat breakdown). In Phase 2 trials, the combined signal produced up to ~24.2% body-weight reduction in obesity over 48 weeks [1] and 2.02% HbA1c reduction in type 2 diabetes over 24 weeks [2]. A 2025 review (Katsi et al.) characterized the weight-loss magnitude as a step-change versus prior incretin therapies [6].
How does retatrutide work?
Retatrutide is a triple agonist (simultaneous activator) at three class-B GPCRs: GIP receptor, GLP-1 receptor, and glucagon receptor. The GLP-1 and GIP arms suppress appetite and enhance glucose-dependent insulin secretion. The glucagon arm boosts energy expenditure and hepatic lipid metabolism — the mechanism that researchers believe drives larger weight loss than dual or single agonists. Cryo-EM structural studies resolved the drug's binding at all three receptor complexes; relative potency is ~8.9× native GIP at GIPR, ~0.4× native GLP-1 at GLP-1R, and ~0.3× native glucagon at GCGR [3].
How to reconstitute retatrutide?
No validated reconstitution protocol exists for retatrutide outside clinical trials. In trials, the compound was administered as pre-prepared pharmaceutical-grade investigational product under Good Manufacturing Practice conditions — participants did not reconstitute it themselves. No approved formulation exists. Improvised reconstitution of gray-market research-labeled material has no pharmaceutical standard behind it. This site does not provide reconstitution instructions.
Is retatrutide FDA approved?
No. Retatrutide is investigational and not approved by the FDA or any regulatory authority as of 2026. It is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. An approved indication, dosing label, or prescription product does not exist. The compound cannot be legally prescribed or dispensed through any pharmacy.
When will retatrutide be available?
No public regulatory filing date has been announced by Eli Lilly as of mid-2026. Phase 3 trials are ongoing. After trials complete, the FDA review process typically takes 12–24 months. Regulatory approval is not guaranteed — Phase 3 may produce unexpected findings. The only current access route is enrollment in an active TRIUMPH trial (ClinicalTrials.gov, search 'LY3437943').
How to take retatrutide?
In clinical trials, retatrutide was administered as a once-weekly subcutaneous (under-skin) injection, with dose escalation starting from a lower dose and stepping up over weeks. This is the study protocol — not personal guidance. Retatrutide is not approved and cannot be lawfully prescribed or obtained through a pharmacy. This site does not provide dosing instructions.
How long does retatrutide take to work?
In Phase 2 trials, weight loss was measurable within the first weeks of treatment and continued through 48 weeks [1]. The full weight-loss effect at the 12-mg dose accumulated over the 48-week trial period, with mean loss reaching ~24.2%. The 2025 pharmacology review (Katsi et al.) noted that the triple-agonist mechanism drives sustained progressive weight loss over the trial period, rather than a rapid early plateau [6]. Timeline data beyond Phase 2 is not yet available from Phase 3.
Is retatrutide better than tirzepatide?
No head-to-head comparison has been published. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon receptor agonism. Phase 2 retatrutide data showed ~24.2% weight loss at 48 weeks [1]; tirzepatide's Phase 3 data showed ~22.5% at 72 weeks in a different trial population. Cross-trial comparisons are not valid. The TRIUMPH program includes an active-comparator trial versus tirzepatide specifically to answer this question. Superiority cannot be claimed until that trial reports.
How much retatrutide per week?
Phase 2 trials studied once-weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, and 12 mg in the obesity trial [1], and 0.5 mg to 12 mg with escalation in the type 2 diabetes trial [2]. These are the dose levels administered in controlled trials — they are study-design facts, not dosing guidance. Retatrutide is not approved; no prescribed dose exists.
How to mix retatrutide with bacteriostatic water?
In clinical trials, retatrutide was not reconstituted with bacteriostatic water — it was provided as a pharmaceutical-grade pre-prepared solution by the trial pharmacy. No validated protocol for mixing gray-market research-labeled retatrutide with bacteriostatic water exists. This site does not provide reconstitution or mixing guidance.
How to switch from tirzepatide to retatrutide?
Retatrutide is not approved and cannot be prescribed. No established switching protocol exists. Tirzepatide is FDA-approved; any changes to its use should be managed by the prescribing physician. Discussion of switching from an approved medicine to an investigational compound is outside the scope of this site, which documents published research only.
Is retatrutide a GLP-3?
No. 'GLP-3' is a misnomer — there is no GLP-3 receptor in humans. Retatrutide is a TRIPLE agonist acting at three distinct receptors: GIP receptor, GLP-1 receptor, and glucagon receptor. The 'GLP-3' label appears to be a shorthand adopted in some community discussions and media, but it is pharmacologically incorrect. The correct designations are 'triple agonist,' 'triagonist,' or 'GIP/GLP-1/glucagon receptor triple agonist' [3][6].
Is retatrutide available?
Not through legitimate channels. Retatrutide has no approved indication and no prescription availability. The only legitimate access is through active Phase 3 clinical trial enrollment (ClinicalTrials.gov). Gray-market research-labeled material exists but is unregulated, of unverified identity and purity, and outside any clinical oversight. The FDA has cited gray-market vendors for Federal FD&C Act violations.
What is retatrutide used for?
In Phase 2 clinical trials, retatrutide has been studied for obesity (weight management in adults with BMI ≥30 or ≥27 plus comorbidity), type 2 diabetes (HbA1c and body-weight reduction), and MASLD (metabolic dysfunction-associated steatotic liver disease). Phase 3 trials extend the study program to cardiovascular outcomes and chronic kidney disease. As an investigational drug, it does not currently have an approved use for any indication.
What receptors does retatrutide target?
Three receptors: (1) GIP receptor (GIPR) — glucose-dependent insulinotropic polypeptide receptor; (2) GLP-1 receptor (GLP-1R) — glucagon-like peptide-1 receptor; (3) glucagon receptor (GCGR). Cryo-EM structures resolved binding at all three [3]. All three are class-B GPCRs (G protein-coupled receptors). Retatrutide signals through cAMP/PKA downstream of all three, with a potency ratio of ~8.9× native GIP at GIPR, ~0.4× native GLP-1 at GLP-1R, ~0.3× native glucagon at GCGR.
Is retatrutide legal?
Retatrutide is not scheduled as a controlled substance. Possessing or using it is not a criminal offense in most jurisdictions. However, it is an unapproved drug: manufacturing, distributing, or selling it outside of an FDA-authorized clinical trial violates the Federal Food, Drug, and Cosmetic Act in the United States. The FDA has issued warning letters to vendors. The legal status in other countries varies; in most regulated markets, distributing an unapproved drug product is prohibited.
How often do you take retatrutide?
In all published Phase 1 and Phase 2 trials, retatrutide was administered once weekly by subcutaneous injection [1][2][4]. The approximately 6-day half-life supports once-weekly dosing — it maintains plasma concentration within the range studied between weekly administrations. This is the trial protocol; it is not a personal dosing instruction.
How to store retatrutide?
No approved storage specification exists for retatrutide outside clinical trials. In clinical trials, investigational product was stored by trial pharmacies under controlled pharmaceutical conditions. Gray-market material has no validated storage specification. Common research-peptide storage practices (refrigerated at 2–8°C, protected from light) are not validated for retatrutide and do not confer pharmaceutical-grade quality.
Is retatrutide the same as Ozempic?
No. Retatrutide (LY3437943) and semaglutide are distinct compounds. Semaglutide is a GLP-1 receptor mono-agonist approved for type 2 diabetes and obesity. Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist — not approved by any regulator. They share GLP-1 receptor agonism but differ in receptor breadth, mechanism, and regulatory status. Retatrutide is not semaglutide in any form.
Is retatrutide better than semaglutide?
No direct head-to-head comparison has been published. Phase 2 retatrutide data showed ~24.2% weight loss at 48 weeks; semaglutide Phase 3 obesity data showed ~14.9% at 68 weeks (STEP 1, different trial population). Cross-trial comparison is not valid. Retatrutide adds GIP and glucagon receptor agonism, which semaglutide lacks; whether the additional mechanistic complexity translates to a clinically meaningful benefit-risk advantage over approved agents will only be established through the Phase 3 TRIUMPH program and its active-comparator designs.